FDA Finalizes NDI Notification Guidance on Ingredient Identity and Safety Evidence

For ingredient manufacturers and dietary supplement distributors planning U.S. market entry, the practical focus is on three questions: What exactly is the ingredient being notified? Does the available evidence support its intended use? How should that evidence be brought together into a defensible safety conclusion?

The guidance sets out FDA's recommendations rather than creating a new approval pathway. Guidance recommendations should be distinguished from obligations established by applicable statutes and regulations.

What Does the Final Guidance Cover?

The final guidance on NDI identity and safety information addresses the preparation and presentation of identity and safety evidence. Compared with the April 2024 version of the revised draft, the revisions cover eight areas:

These topics should be considered together. A safety study or history of consumption is useful only to the extent that it is relevant to the ingredient and conditions of use described in the notification.

Ingredient Identity Must Be Linked to the Safety Evidence

A clear description of ingredient identity provides the foundation for an NDI safety assessment. Manufacturers should explain the ingredient's composition, production process and quality characteristics sufficiently to establish what is being evaluated.

A trade name or the concentration of a single marker compound may not fully characterize an ingredient. Depending on the material, relevant information may include physicochemical characteristics, identification methods, manufacturing processes, specifications, controls on batch variability, and safety-related impurities or contaminants.

The emphasis varies by ingredient type. For botanicals and extracts, source material, plant part and extraction or processing conditions can affect the identity assessment. Fermentation-derived ingredients call for information on the production microorganism and fermentation process. For live microbial ingredients, strain identification and the relationship to strains represented in the safety evidence require particular attention.

When relying on published studies or historical consumption, manufacturers should explain how the material described in those sources compares with the ingredient proposed for notification. Differences in composition or manufacturing may affect whether the evidence can support the intended product.

Safety Evidence Should Address the Intended Conditions of Use

The safety assessment should explain why the dietary supplement containing the NDI can reasonably be expected to be safe under its intended conditions of use. Relevant considerations include the amount consumed per serving, total daily intake, frequency and duration of use, and intended population.

Historical consumption therefore needs to be assessed in context. For example, consumption of a botanical as a conventional food does not automatically establish the safety of a highly concentrated extract taken daily over an extended period. Composition, intake and patterns of use should be compared.

Likewise, a new manufacturing process, higher proposed intake or different target population may create gaps between the available evidence and the intended use. Identifying those gaps early helps manufacturers determine whether existing information is sufficient or further evidence is needed.

NAMs Require a Clear Scientific Justification

The final guidance also discusses alternative methods, including in vitro and computational approaches. FDA supports their use where the resulting data are scientifically valid and appropriate for the intended assessment. Manufacturers using NAMs should explain their reliability, suitability and limitations.

The guidance does not establish a general exemption from animal studies. Study selection should reflect the specific evidence gap and the available safety information, rather than an assumption that one method or a fixed testing package will suit every NDI.

Which NDI Guidance Documents Are Final?

FDA has been addressing individual topics from the 2016 revised draft through separate guidance documents. The October 2026 publication does not finalize the entire original document.

FDA's consolidated draft guidance page was also revised in October 2026 to identify the newly finalized sections. FDA states that it plans to finalize other sections as its review progresses.

What Should Manufacturers Do Before Preparing an NDIN?

For products subject to the notification requirement, the manufacturer or distributor must submit an NDIN at least 75 days before introducing or delivering the product for introduction into U.S. interstate commerce. Whether notification is required should be assessed for the specific ingredient and proposed use.

REACH24H recommends starting with a gap assessment of ingredient identity, manufacturing information and specifications. The proposed intake, intended population and duration of use should then be defined before evaluating how far historical consumption and existing studies can support the product.

This sequence helps avoid commissioning studies before the product's intended use and evidence needs are clear. It also allows regulatory and product development teams to identify discrepancies between the commercial ingredient, the material used in studies and the proposed notification.

REACH24H provides U.S. FDA NDI notification support, including notification applicability and feasibility assessments, organization of supporting documentation, and notification preparation and submission.

Official References

• FDA announcement: Identity and safety information for NDI notifications

• Final guidance: NDI identity and safety information

• Revised draft guidance and finalization history

• FDA NDI notification process

• Final guidance: Notification procedures and timeframes

• Draft guidance: NDI notification master files